mantle cell lymphoma
Market Access/ News/ News/ News/ Oncology
Gilead’s Kite gains some height after second CAR-T approval in US
Phil Taylor
CAR T, Gilead Sciences, immuno-oncology, Kite Pharma, mantle cell lymphoma, Oncology
0 Comment
Market Access/ News/ News/ News/ Oncology
Gilead closes in on second CAR-T approval in US
Phil Taylor
fda, Gilead Sciences, immuno-oncology, Kite Pharma, mantle cell lymphoma, Oncology, Priority Review
0 Comment
Market Access/ News/ News/ News/ Oncology
EMA starts review of second CAR-T from Gilead’s Kite unit
Phil Taylor
CAR T, Gilead Sciences, immuno-oncology, Kite Pharma, mantle cell lymphoma, Oncology
0 Comment
Gilead to file new CAR-T, setting up potential mid-2020 launch
Richard Staines
cancer, CAR T, Gilead, mantle cell lymphoma, Novartis
0 Comment
Calquence approval another win for AstraZeneca in oncology
Andrew McConaghie
AstraZeneca, mantle cell lymphoma
0 Comment
News/ Pharma Market Access/ Top stories/ UK & Europe
Janssen’s Imbruvica runs into trouble with NICE in mantle cell lymphoma
Richard Staines
blood cancer, cancer, Cancer Drugs Fund, Johnson & Johnson, mantle cell lymphoma, UK market access
0 Comment
NICE suggests interim CDF funding while further data is gathered.